Immpheron

Immpheron is a biotechnology company focused on developing next-generation cancer immunotherapies through its proprietary Imm-Link platform. The company's technology is designed to create bispecific antibodies and fusion proteins that more effectively bridge the immune system to tumor cells while minimizing off-target toxicity. By optimizing the binding kinetics and structural orientation of immune-engaging molecules, Immpheron aims to overcome the limitations of current T-cell engagers in treating solid tumors. The company is currently advancing a pipeline of pre-clinical candidates targeting well-validated tumor antigens such as EGFR and CEA.